
Opinion|Videos|March 21, 2025
Navigating the Boxed Warning for the JAK Inhibitor Class
Panelists discuss how clinicians can interpret and apply the JAK inhibitor class boxed warning to make informed treatment decisions while weighing potential risks against therapeutic benefits for individual patients.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Grants Breakthrough Therapy Designation to Litifilimab for Cutaneous Lupus Erythematosus
2
Del Rosso's What's New in the Medicine Chest 2026: CHE, CSU, and Vitiligo
3
Multi-Ingredient Topical Treatment Significantly Improves Wrinkles and Skin Thickness in Patients with "Ozempic Face"
4
On the Horizon: Innovations in the Acne Treatment Pipeline
5








